News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Increases speed to market for drug developers working on nucleic acid therapeutics
Acquisition expands high-value medical platform
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
Subscribe To Our Newsletter & Stay Updated
